Product
Spiriva®Handihaler®
1 clinical trial
1 indication
Indication
Chronic Obstructive Pulmonary DiseaseClinical trial
A Single-Center, Open-Label, Randomized, Single-Dose, Two-Period, Two-Sequence, Crossover Trial to Assess the Bioequivalence of Test Product Tiotropium Bromide Inhalation Powder (Strength: 18 mcg) and Reference Product (Spiriva®Handihaler®, Strength: 18 mcg) in Healthy Adult Participants Under Fasting ConditionsStatus: Active (not recruiting), Estimated PCD: 2024-08-01